1.26
3.46%
-0.04
After Hours:
1.26
Lineage Cell Therapeutics Inc stock is currently priced at $1.26, with a 24-hour trading volume of 1.22M.
It has seen a -3.46% decreased in the last 24 hours and a -10.36% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.26 pivot point. If it approaches the $1.44 resistance level, significant changes may occur.
Previous Close:
$1.30
Open:
$1.31
24h Volume:
1.22M
Market Cap:
$245.44M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-9.6923
EPS:
-0.13
Net Cash Flow:
$-29.24M
1W Performance:
+15.14%
1M Performance:
-10.36%
6M Performance:
+11.06%
1Y Performance:
-12.24%
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-02-22 | Initiated | Robert W. Baird | Outperform |
Jun-14-22 | Initiated | B. Riley Securities | Buy |
Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
Benzinga
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Lineage Cell Therapeutics Inc (LCTX) Revenue 2024
LCTX reported a revenue (TTM) of $8.95 million for the quarter ending December 31, 2023, a -39.16% decline year-over-year.
Lineage Cell Therapeutics Inc (LCTX) Net Income 2024
LCTX net income (TTM) was -$21.49 million for the quarter ending December 31, 2023, a +18.22% increase year-over-year.
Lineage Cell Therapeutics Inc (LCTX) Cash Flow 2024
LCTX recorded a free cash flow (TTM) of -$29.24 million for the quarter ending December 31, 2023, a -4,626% decrease year-over-year.
Lineage Cell Therapeutics Inc (LCTX) Earnings per Share 2024
LCTX earnings per share (TTM) was -$0.12 for the quarter ending December 31, 2023, a +20.00% growth year-over-year.
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Cap:
|
Volume (24h):